The University of Michigan Comprehensive Cancer Center is celebrating honors bestowed upon two individuals who have made significant contributions to cancer treatment and care. Both work at the U-M Breast Care Center, which was the first academic multidisciplinary breast care center in the country and celebrated its 25th anniversary in 2010.
Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to recent findings by University of Michigan Comprehensive Cancer Center researchers. The results were presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, which was held in Lake Tahoe, Nevada, in June.
A research team led by the University of Michigan found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.
The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59% of patients, a new study led by a University of Michigan Comprehensive Cancer Center researcher finds. This is the first clinical trial to find an effective treatment for this pain.
They came from across Michigan and as far away as California to show their mettle -- and their generosity -- on the gridiron at the Big House.
Kidney cancer patients who had only their tumor removed had better survival than patients who had their entire kidney removed, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
Welcome to the summer edition of the U-M cancer e-newsletter. As usual, the last few months have been busy and exciting here at the Comprehensive Cancer Center! I'm pleased to be able to share some of the ways that U-M researchers are making great strides in understanding, diagnosing, preventing and treating cancer.